The University of Texas MD Anderson Cancer Center and Sibylla Biotech announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders, which disrupt the proper folding of target proteins and lead to their degradation.
Atlantic Health System, an integrated health care system setting standards for quality health care, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System at the Carol G. Simon Cancer Center.
FDA approved lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.
FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.
Directors of NCI-designated cancer centers are facing a new set of challenges in a polarizing, high-stakes election year.
Christopher Li, the Helen G. Edson Endowed Chair for Breast Cancer Research at Fred Hutchinson Cancer Center, understands what it means to be an underrepresented minority at each stage of his academic career.
Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.
In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1
Dennis Slamon, an oncologist and scientist whose research has transformed the treatment of breast cancer, was awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.
Susan BullmanXi ChenSusan Bullman and Xi Chen were named associate members at the James P. Allison Institute at MD Anderson Cancer Center.
